The prognostic value of metformin for cancer patients with concurrent diabetes: A systematic review and meta-analysis

Diabetes, Obesity and Metabolism

Volumn 16, Issue 8, 2014, Pages 707-710

  Zhang, Z J ^a   Li, S ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Cancer; Cancer specific survival; Metformin; Prognosis; Survival

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COLORECTAL CANCER; DIABETES MELLITUS; ENDOMETRIUM CANCER; HUMAN; LARYNX CANCER; LIVER CANCER; LUNG CANCER; META ANALYSIS; MORTALITY; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RISK FACTOR; SYSTEMATIC REVIEW; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; COMPLICATION; DIABETES COMPLICATIONS; ENDOMETRIAL NEOPLASMS; EVIDENCE BASED MEDICINE; FEMALE; MALE; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DIABETES COMPLICATIONS; ENDOMETRIAL NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MORTALITY; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84904398047     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12267     Document Type: Article

References (35)

1. Zhang ZJ, Zheng ZJ, Kan H et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34: 2323-2328.
2. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 2347-2353.
3. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010; 17: 351-360.
4. Nair V, Pathi S, Jutooru I et al. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 2013; 34: 2870-2879.
5. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci 2013; 34: 126-135.
6. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2012; 23: 1771-1780.
7. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013; 36: 3018-3026.
8. Bayraktar S, Hernadez-Aya LF, Lei X et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012; 118: 1202-1211.
9. Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of 1, 013 breast cancer patients with diabetes. Breast Cancer Res Treat 2013; 137: 807-816.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
12. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299-304.
13. Kumar S, Meuter A, Thapa P et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 2013; 119: 555-562.
14. Peeters PJ, Bazelier MT, Vestergaard P et al. Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013; 8: 357-363.
15. Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. Tumour Biol 2014; 35: 2035-2045.
16. Cossor FI, Adams-Campbell LL, Chlebowski RT et al. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol 2013; 37: 742-749.
17. Garrett CR, Hassabo HM, Bhadkamkar NA et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012; 106: 1374-1378.
18. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012; 131: 752-759.
19. Spillane S, Bennett K, Sharp L, Barron TI. A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013; 22: 1364-1373.
20. Romero IL, McCormick A, McEwen KA et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012; 119: 61-67.
21. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011; 22: 2640-2645.
22. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013; 63: 709-716.
23. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2014; 32: 43.e1-43.e7.
24. Margel D, Urbach DR, Lipscombe LL et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31: 3069-3075.
25. Allott EH, Abern MR, Gerber L et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis 2013; 16: 391-397.
26. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18: 2905-2912.
27. Nakai Y, Isayama H, Sasaki T et al. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas 2013; 42: 202-208.
28. Hwang AL, Haynes K, Hwang WT, Yang YX. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 2013; 42: 1054-1059.
29. Tan BX, Yao WX, Ge J et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011; 117: 5103-5111.
30. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2013; 12: 410.
31. Nevadunsky NS, Van Arsdale A, Strickler HD et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2014; 132: 236-240.
32. Ko EM, Walter P, Jackson A et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2013.
33. Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011; 26: 858-865.
34. Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2014; 36: 1039-1043.
35. Rieken M, Xylinas E, Kluth L et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol 2014; 32: 49.e7-49.e14.